Recommended Starting Dose for Lunesta Lowered by FDA - Risk of Morning Impairment

FDA has lowered the recommended starting dose of the sleep drug Lunesta® (eszopiclone) from 2 mg to 1 mg. Patients who are currently taking 2 mg and 3 mg doses of eszopiclone should contact their health care provider to ask for instructions on how to continue to take their medication safely at a dose that is best for them, FDA advises. The dose change came after findings from a study of 91 healthy adults found that the medication was associated with impairment to driving skills, memory, and coordination for as long as 11 hours after the drug is taken. In January 2013, FDA announced a similar dose reduction for sleep medications that contain the active ingredient zolpidem, such as Ambien® and Ambien CR.
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm397453.htm